GS 5745

Drug Profile

GS 5745

Alternative Names: GS-5745; MMP9 mAb inhibitor - Gilead

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastric cancer
  • Phase II/III Ulcerative colitis
  • Phase II Crohn's disease; Cystic fibrosis; Rheumatoid arthritis
  • Phase I Chronic obstructive pulmonary disease
  • No development reported Solid tumours

Most Recent Events

  • 09 Nov 2016 Phase-II clinical trials in Rheumatoid arthritis (Adjunctive treatment) in USA, Australia, Germany, Hungary, Mexico, Taiwan and Belgium (SC) (Gilead Sciences pipeline, November 2016)
  • 21 Sep 2016 Gilead Sciences terminates a phase II/III trial in Ulcerative Colitis in USA, United Kingdom, Ukraine, Taiwan, Sweden, Spain, South Korea, South Africa, Slovakia, Serbia, Russia, Romania, Poland, New Zealand, Netherlands, Latvia, Italy, Israel, Iceland, Ireland, Hungary, Hong Kong, Germany, France, Czech Republic, Croatia, Canada, Bulgaria, Belgium, Austria and Australia after the trial met the pre-specified futility and efficacy criteria
  • 01 Sep 2016 Phase-I clinical trials in Gastric cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent, Combination therapy) in Japan (IV) (NCT02862535)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top